LODC
COCP icon

Lanham O'Dell & Company’s Cocrystal Pharma COCP Stock Holding History

Lanham O'Dell & Company’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000
Closed -$8K – 22
2021
Q4 		$8K Buy
+1,000
New +$10.2K 0.01% 22

Other funds holding COCP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lanham O'Dell & Company's COCP Position: Q1 2022 in Review

Lanham O'Dell & Company sold out of Cocrystal Pharma (COCP) in Q1 2022, closing a stake of 1,000 shares — an estimated $8K sold.

Lanham O'Dell & Company first reported a position in COCP in Q4 2021 and held it in 1 quarter. The position peaked at $8K in Q4 2021. 34 funds tracked by Wall St. Rank hold COCP as of Q1 2022.

  • Lanham O'Dell & Company reported no remaining Cocrystal Pharma position as of Q1 2022 after selling out during the quarter.
  • Lanham O'Dell & Company sold 1,000 Cocrystal Pharma shares in Q1 2022, an estimated $8K.
  • Lanham O'Dell & Company first reported a position in Cocrystal Pharma in Q4 2021 and held it in 1 quarter.
  • Lanham O'Dell & Company's Cocrystal Pharma position peaked at $8K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q1 2022.

Based on Lanham O'Dell & Company's 13F filing for Q1 2022, filed 12 May 2022.